Taiwan-based focused ultrasound manufacturer NaviFUS recently announced the start of its first clinical trial for glioblastoma. To date, three patients have been treated. Researchers at Chang Gung Memorial Hospital are investigating focused ultrasound to induce opening of the blood-brain barrier (BBB) in patients with glioblastoma using optically guided, neuronavigational technology…
The 6th International Symposium on Focused Ultrasound (ISFU) was held in Reston, Virginia, demonstrating the field’s immense progress and the groundbreaking technology’s potential to transform medical therapy worldwide. More than 450 clinicians, scientists, government employees and industry representatives from around the globe gathered October 21–25 to hear 250 presentations on the latest research, including key clinical milestones for neurological indications such as brain tumors, epilepsy, Parkinson’s disease, Alzheimer’s disease, OCD, and depression.
Chief Executive Officer Dr. Lung participate in this symposium and disclosed the initial safety result of FIH trial about ” FUS Open BBB” in rGBM patient at Linkou Chang Gung Memorial Hospital (Taiwan)…
The NaviFus Focus Ultrasound System has been getting investigational Device Exemption (IDE) qualification and accepted to execute FIH clinical trial in Q1 for rGBM patients by TFDA Consulting.
It’s a pioneer of brain tumor therapy by using FUS opening BBB temporally in Taiwan’s clinical study. In addition to brain tumors, it is also actively expanding the use of this technology in other central nervous diseases, such as Alzheimer’s disease, epilepsy and so on…
“Future Tech, 2017” in Taiwan assembles 109 breakthroughs and industrial applications of forward-looking technology’s research achievements from72 study institutes to participate such as MOST、Science Park、NARLABS、NIH, NSRRC, NCDR… etc. The area including biotechnology and new drugs, Medical materials, electronics and optoelectronics, metal chemicals and innovative materials.
The prototype of Navifus System is also debuted in the exhibition, the system can guide the specific frequency ultrasound to the appropriate position of the temporary opening blood-brain barrier (BBB) and enhance the treatment by helping the drug release.
